Our Science

There have been very few new therapies in the critical care arena over the past half a century. Ikaria is committed to changing that.

We use our scientific expertise to develop biotherapeutic solutions for the critical care market. Our research continues to break new ground toward our goal of improving the clinical outcomes for critically ill patients. INOMAX® (nitric oxide) for inhalation is our first commercialized product and demonstrates our ability to develop therapies that meet the significant unmet needs of these patients. But it’s only just the start (see Current R&D).

"Ikaria is focused on the most critically ill patients in the hospital.

And we are committed to supporting the R&D needed to deal with the complexities of critical care conditions. Our science holds promise for real advancements in the critical care space, providing time and 'breathing room' for healthcare professionals to treat. How many companies can say they aspire to do that?"